Please use this identifier to cite or link to this item:
Title: Relationship between QT Interval Length and Arterial Stiffness in Systemic Lupus Erythematosus (SLE): A Cross-Sectional Case-Control Study.
Authors: Rivera-López, Ricardo
Jiménez-Jáimez, Juan
Sabio, José Mario
Zamora-Pasadas, Mónica
Vargas-Hitos, José Antonio
Martínez-Bordonado, Josefina
Navarrete-Navarrete, Nuria
Fernández, Ricardo Rivera
Sanchez-Cantalejo, E
Jiménez-Alonso, Juan
metadata.dc.subject.mesh: Adult
Carotid Intima-Media Thickness
Case-Control Studies
Cross-Sectional Studies
Follow-Up Studies
Long QT Syndrome
Lupus Erythematosus, Systemic
Middle Aged
Pulse Wave Analysis
Risk Factors
Vascular Stiffness
Issue Date: 11-Apr-2016
Abstract: The QT interval on the electrocardiogram has been shown to be longer in patients with systemic lupus erythematosus (SLE) compared to that of the general population. The clinical significance of this finding is unknown. The aim of this study was to assess the relationship between QT interval and subclinical atherosclerosis, measured by carotid-femoral pulse-wave velocity. 93 patients with SLE and 109 healthy women with similar basal characteristics were studied. All patients underwent a 12- lead electrocardiogram, and corrected QT interval (QTc) was measured using the Bazett's formula. The presence of atherosclerosis was evaluated by carotid-femoral pulse-wave velocity. Clinical basal characteristics were similar in both groups. QTc interval was 415 ± 21.4 milliseconds in all patients, and 407 ± 19.1 milliseconds in the control group (p = 0.007). There was a positive correlation between QTc interval and carotid-femoral pulse-wave velocity (r = 0.235; p = 0.02) in patients with SLE. This association was independent of hypertension and age in a multivariate analysis. QTc interval measured by electrocardiogram is prolonged in SLE patients; it is related to subclinical atherosclerosis, measured by carotid-femoral pulse-wave velocity. This measure may help stratify risk in routine clinical practice and select the patients that might benefit from a more aggressive therapy in the prevention of cardiovascular events.
metadata.dc.identifier.doi: 10.1371/journal.pone.0152291
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC4827799.pdf653,04 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons